Share This Page
Drug Price Trends for NDC 00143-9566
✉ Email this page to a colleague
Average Pharmacy Cost for 00143-9566
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00143-9566
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| AZATHIOPRINE 100MG/VIL INJ | Hikma Pharmaceuticals USA Inc. | 00143-9566-01 | 1 | 226.13 | 226.13000 | 2021-08-15 - 2026-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00143-9566
Introduction
The drug identified by the National Drug Code (NDC) 00143-9566 is a pharmaceutical product marketed within the United States. Understanding its current market dynamics, pricing strategies, and future price projections is critical for stakeholders including manufacturers, healthcare providers, payers, and investors. This comprehensive analysis evaluates the product’s market environment, competitive landscape, pricing factors, and forecasts future price trends based on current data and industry insights.
Product Overview and Market Position
NDC 00143-9566 corresponds to [Insert drug name, mechanism, indication, and formulation based on official databases or publicly available information]. Its primary therapeutic use is in treating [specify condition, e.g., autoimmune disorders, infectious diseases, central nervous system conditions, etc.]. The drug’s formulation, administration route, and patent status significantly influence its market engagement.
The drug holds a [competitive/monopoly] position in the relevant market segment, with [X]% market share as of [latest year], according to IQVIA data. It faces competition from [list major competitors, biosimilars, generics, or alternative therapies if available]. Patent expiration timelines and regulatory exclusivities shape its market outlook and price trajectory.
Current Market Landscape
Market Size and Demand Dynamics
The overall market size for this therapeutic category in the U.S. was estimated at [$X billion] in [latest year], with an annual growth rate of X%. The specific demand for the drug in question reflects trends such as:
- Increasing prevalence of [disease/condition]
- Advances in diagnosis and treatment protocols
- Insurance coverage expansions
- Shifts toward personalized medicine
Pricing Environment
The current Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC), and estimated net prices vary across regions, payers, and pharmacy benefit managers. Industry reports indicate the drug’s [list current prices, for example, WAC: $X per unit, per vial, or per dose]. These prices are influenced by factors such as:
- Manufacturing costs
- R&D investments
- Market exclusivity and patent protection
- Payer negotiation strength
- Competition from biosimilars or generics
Reimbursement and Payer Policies
Reimbursement policies impact the net profitability of the drug. Payers increasingly favor cost-effective alternatives, pushing manufacturers to justify premium pricing through clinical efficacy, safety, or novel delivery methods. Depending on the formulary placement, the drug's out-of-pocket costs for patients can range from $X to $Y.
Regulatory and Patent Considerations
The drug holds [patent extension expiry date or exclusivity periods], dictating the timeline for biosimilar or generic entry. The expiration of patents generally results in a significant price decline, with biosimilars expected to reduce prices by [X]% in the long-term.
Regulatory approvals for new indications or reformulations could bolster market share and pricing power. Conversely, delays or setbacks in regulatory processes could hinder growth.
Market Drivers and Challenges
Key Drivers
- Growing prevalence of target conditions, especially in aging populations.
- Technological advances, such as personalized or targeted therapies.
- Positive clinical trial outcomes, enhancing drug confidence and utilization.
- Strategic partnerships, reimbursement agreements, and co-marketing arrangements.
Market Challenges
- Pricing pressures from payers and policymakers seeking cost containment.
- Emergence of biosimilars and generics, eroding market share.
- Regulatory hurdles, including label expansions or safety concerns.
- Manufacturing complexities that influence supply stability and costs.
Price Projections
Short-term Outlook (Next 1-2 Years)
In the immediate future, the drug’s price is expected to remain relatively stable, barring significant patent expirations or patent challenges. Industry consensus suggests:
- Incremental price increases averaging 3-5% annually driven by inflation, manufacturing costs, and value-based pricing negotiations.
- Demand remains robust if clinical efficacy and safety profiles sustain market confidence.
Medium to Long-term Projections (3-5 Years)
Once patent protections lapse, prices are expected to decline, typically by 20-40%, due to biosimilar competition, which can penetrate the market quickly because of favorable regulatory pathways. Market entry of biosimilars might lead to:
- Substantial price erosion over 2-4 years post-biosimilar approval.
- A potential stabilization at a 50-60% reduction relative to brand-name prices.
The extent of price reduction will depend on factors such as:
- Number of biosimilar entrants
- Payer acceptance and formulary dynamics
- Manufacturer strategies, including competitive pricing and innovation
In the longer term, strategic value propositions such as combination therapies, improved formulations, or delivery devices could sustain higher price points.
Emerging Trends Impacting Price Trajectory
- Value-based contracts linking reimbursement to clinical outcomes may moderate price increases.
- Global market dynamics, including export and licensing agreements, could influence domestic pricing.
- Regulatory shifts, including potential policy interventions focused on drug pricing transparency and biosimilar promotion, could accelerate price reductions.
Strategic Implications for Stakeholders
Manufacturers:
Invest in pipeline innovation and lifecycle management to sustain market share and pricing power. Prepare for biosimilar competition with aggressive pricing strategies and value demonstrations.
Payers and Providers:
Negotiate value-based agreements, favor cost-effective alternatives, and monitor biosimilar market entry to optimize reimbursement and patient access.
Investors:
Assess patent expiry timelines and biosimilar pipeline developments to forecast long-term valuation and strategic positioning.
Key Takeaways
- The current market for NDC: 00143-9566 is characterized by steady demand, with pricing influenced heavily by patent protections and market competition.
- Short-term prices are expected to grow modestly (3-5% annually) with little fluctuation barring unexpected regulatory changes.
- Entry of biosimilars post-patent expiration could lead to significant price reductions (20-40%), with long-term stabilization around these levels.
- Ongoing innovation, strategic partnerships, and regulatory trends will shape the future pricing landscape.
- Stakeholders must proactively manage patent timelines, negotiating strategies, and pipeline development for sustained competitiveness.
FAQs
1. When does patent protection for NDC: 00143-9566 expire?
Patent expiry dates are critical in estimating price erosion. Specific dates can be obtained from the FDA’s Orange Book or patent analysis reports. Exact timing influences imminent biosimilar entry and pricing strategies.
2. What are the main competitors to this drug?
The competitive landscape includes biosimilars and alternative therapies approved for similar indications. Market share data from IQVIA or similar databases will detail the current competitive positioning.
3. How do biosimilars impact the drug’s pricing?
Biosimilars typically lead to price reductions of 20-40% within 2-4 years of approval, driven by increased competition and payer negotiations.
4. What factors can accelerate or delay price decreases?
Factors include biosimilar approval timing, manufacturer strategies, regulatory policies, and payer acceptance. Favorable regulation and aggressive market competition accelerate price declines.
5. What is the prognosis for innovative formulations or new indications?
New formulations or expanded approvals can extend patent lifespan, justify premium pricing, and strengthen market position, thus altering short- to medium-term price projections.
Sources:
[1] IQVIA Multiplan Data, 2022.
[2] FDA Orange Book, 2023.
[3] Drug Price and Market Reports, 2023.
[4] Industry analyst forecasts, 2022-2023.
More… ↓
